1. Shah JP, Gil Z. Current concepts in management of oral cancer-sur- gery. Oral Oncol. 2009;45:394-401.
2. Pulte D, Brenner H. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist. 2010;15:994-1001.
3. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
4. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 1991;325(23):1593-1596.
5. Yokoyama U, Iwatsubo K, Umemura M, Fujita T, Ishikawa Y. The prostanoid EP4 receptor and its signaling pathway. Pharmacol Rev. 2013;65:1010-1052.
6. Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem. 2007;282:11613-11617.
7. Luschnig-Schratl P, Sturm EM, Konya V, et al. EP4 receptor stimu- lation down-regulates human eosinophil function. Cell Mol Life Sci. 2011;68:3573-3587.
8. Tamiji J, Crawford DA. Misoprostol elevates intracellular calcium in neuro-2a cells via protein kinase A. Biochem Biophys Res Comm. 2010;399:565-570.
9. Putney JW. Capacitative calcium entry. sensing the calcium stores. J Cell Biol. 2005;169:381-382.
10. Johnson M, Trebak M. ORAI channels in cellular remodeling of car-diorespiratory disease. Cell Calcium. 2019;79:1-10.
11. Feske S, Gwack Y, Prakriya M, et al. A mutation in Orai1 causes immune deficiency by abrogating CRAC channel function. Nature. 2006;441:179-185.
12. Ong HL, Ambudkar IS. The dynamic complexity of the TRPC1 chan-nelosome. Channels. 2011;5:424-431.
13. Umemura M, Baljinnyam E, Feske S, et al. Store-operated Ca2+ entry (SOCE) regulates melanoma proliferation and cell migration. PLoS ONE. 2014;9:e89292.
14. Kataoka K, Takikawa Y, Lin SD, Suzuki K. Prostaglandin E2 recep- tor EP4 agonist induces Bcl-xL and independently activates pro- liferation signals in mouse primary hepatocytes. J Gastroenterol. 2005;40:610-616.
15. Toyoda Y, Morimoto K, Suno R, et al. Ligand binding to human pros- taglandin E receptor EP4 at the lipid-bilayer interface. Nat Chem Biol. 2019;15:18-26.
16. Säfholm J, Manson ML, Bood J, et al. Prostaglandin E2 inhibits mast cell–dependent bronchoconstriction in human small airways through the E prostanoid subtype 2 receptor. J Allergy Clin Immunol. 2015;136(1232–9):e1.
17. Sato I, Umemura M, Mitsudo K, et al. Simultaneous hyperther- mia-chemotherapy with controlled drug delivery using single-drug nanoparticles. Sci Rep. 2016;6:24629.
18. Nakakaji R, Umemura M, Mitsudo K, et al. Treatment of oral cancer using magnetized paclitaxel. Oncotarget. 2018;9:15591-15605.
19. Akimoto T, Umemura M, Nagasako A, et al. Alternating mag- netic field enhances cytotoxicity of compound C. Cancer Sci. 2018;109:3483-3493.
20. Umemura M, Islam MR, Fukumura H, et al. Simultaneous hyper- thermia-chemotherapy effect by arterial injection of Fe(Salen) for femur tumor. Cancer Sci. 2019;110:356-365.
21. Baljinnyam E, Umemura M, Chuang C, et al. Epac1 increases mi- gration of endothelial cells and melanoma cells via FGF2-mediated paracrine signaling. Pigment Cell Melanoma Res. 2014;27:611-620.
22. Tanaka R, Umemura M, Narikawa M, et al. Hydrostatic pressure suppresses fibrotic changes via Akt/GSK-3 signaling in human car- diac fibroblasts. Physiol Rep. 2018;6:e13687.
23. Narikawa M, Umemura M, Tanaka R, et al. Acute hyperthermia in- hibits TGF-β1-induced cardiac fibroblast activation via suppression of akt signaling. Sci Rep. 2018;8:6277.
24. Baljinnyam E, Umemura M, De Lorenzo MS, et al. Epac1 promotes melanoma metastasis via modification of heparan sulfate. Pigment Cell Melanoma Res. 2011;24:680-687.
25. Kato Y, Yokoyama U, Yanai C, et al. Epac1 deficiency attenuated vascular smooth muscle cell migration and neointimal formation. Arterioscler Thromb Vasc Biol. 2015;35:2617-2625.
26. Oda K, Umemura M, Nakakaji R, et al. Transient receptor potential cation 3 channel regulates melanoma proliferation and migration. J Physiol Sci. 2017;67:497-505.
27. Yokoyama U, Ishiwata R, Jin M-H, et al. Inhibition of EP4 signaling attenuates aortic aneurysm formation. PLoS ONE. 2012;7:e36724.
28. Mamun A, Yokoyama U, Saito J, et al. A selective antagonist of pros- taglandin E receptor subtype 4 attenuates abdominal aortic aneu- rysm. Physiol Rep. 2018;6:e13878.
29. Fujino H, Xu W, Regan JW. Prostaglandin E2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extra- cellular signal-regulated kinases. J Biol Chem. 2003;278:12151-12156.
30. Cherukuri DP, Chen XBO, Goulet A-C, et al. The EP4 receptor an- tagonist, L-161,982, blocks prostaglandin E2-induced signal trans- duction and cell proliferation in HCA-7 colon cancer cells. Exp Cell Res. 2007;313:2969-2979.
31. Doherty GA, Byrne SM, Molloy ES, et al. Proneoplastic effects of PGE2mediated by EP4 receptor in colorectal cancer. BMC Cancer. 2009;9:207.
32. Majumder M, Nandi P, Omar A, Ugwuagbo K, Lala P. EP4 as a ther- apeutic target for aggressive human breast cancer. Int J Mol Sci. 2018;19:1019.
33. Yang L, Huang Y, Porta R, et al. Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 re- ceptor antagonism. Can Res. 2006;66:9665-9672.
34. Kim JI, Lakshmikanthan V, Frilot N, Daaka Y. Prostaglandin E2 pro- motes lung cancer cell migration via EP4-betaArrestin1-c-Src sig- nalsome. Mol Cancer Res. 2010;8:569-577.
35. Spinella F, Rosanò L, Di Castro V, Natali PG, Bagnato A. Endothelin- 1-induced prostaglandin E2-EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion. J Biol Chem. 2004;279:46700-46705.
36. Li Z, Zhang Y, Kim WJ, Daaka Y. PGE2 promotes renal carcinoma cell invasion through activated RalA. Oncogene. 2012;32:1408.
37. Berridge MJ, Bootman MD, Roderick HL. Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol. 2003;4:517-529.
38. Chuderland D, Seger R. Calcium regulates ERK signaling by modulating its protein-protein interactions. Commun Integr Biol. 2008;1:4-5.
39. Tanimura S, Takeda K. ERK signalling as a regulator of cell motility. J Biochem. 2017;162:145-154.
40. Glading A, Chang P, Lauffenburger DA, Wells A. Epidermal growth factor receptor activation of calpain is required for fibroblast mo- tility and occurs via an ERK/MAP kinase signaling pathway. J Biol Chem. 2000;275:2390-2398.
41. Dayton WRGD, Zeece MG, Robson RM, et al. A Ca2+-activated pro- tease possibly involved in myofibrillar protein turnover. Purification from porcine muscle. Biochemistry. 1976;15:2015-2018.
42. Ackermann A, Brieger A. The role of nonerythroid spectrin II in can-cer. J Oncol. 2019;2019:14.
43. Yang F, Yu N, Wang H, et al. Downregulated expression of hepato- ma-derived growth factor inhibits migration and invasion of pros- tate cancer cells by suppressing epithelial-mesenchymal transition and MMP2, MMP9. PLoS ONE. 2018;13:e0190725.
44. Jiang Y, Liang Y, Li L, et al. Targeting neddylation inhibits intravascu- lar survival and extravasation of cancer cells to prevent lung-cancer metastasis. Cell Biol Toxicol. 2019;35:233-245.
45. Yeh C-M, Hsieh M-J, Yang J-S, et al. Geraniin inhibits oral cancer cell migration by suppressing matrix metalloproteinase-2 acti- vation through the FAK/Src and ERK pathways. Environ Toxicol. 2019;34(10):1085-1093.
46. Zhang D, Lu C, Ai H. Rab5a is overexpressed in oral cancer and promotes invasion through ERK/MMP signaling. Mol Med Rep. 2017;16:4569-4576.
47. Ma X, Kundu N, Collin PD, et al. Frondoside A inhibits breast cancer metastasis and antagonizes prostaglandin E receptors EP4 and EP2. Breast Cancer Res Treat. 2012;132:1001-1008.
48. Liao Y, Erxleben C, Yildirim E, et al. Orai proteins interact with TRPC channels and confer responsiveness to store depletion. Proc Natl Acad Sci. 2007;104:4682-4687.
49. Liao Y, Plummer NW, George MD, Abramowitz J, Zhu MX, Birnbaumer L. A role for Orai in TRPC-mediated Ca2+ entry sug- gests that a TRPC: orai complex may mediate store and receptor operated Ca2+ entry. Proc Natl Acad Sci. 2009;106:3202-3206.
50. Feske S. CRAC channels and disease – from human CRAC chan- nelopathies and animal models to novel drugs. Cell Calcium. 2019;80:112-116.
51. Yokoyama U, Minamisawa S, Shioda A, et al. Prostaglandin E2 in- hibits elastogenesis in the ductus arteriosus via EP4 signaling. Circulation. 2014;129:487-496.
52. Ghigo A, Laffargue M, Li M, Hirsch E. PI3K and Calcium Signaling in Cardiovascular Disease. Circ Res. 2017;121:282-292.
53. Campa CC, Ciraolo E, Ghigo A, Germena G, Hirsch E. Crossroads of PI3K and Rac pathways. Small GTPases. 2015;6:71-80.
54. Yang B, Jia L, Guo Q,Ren H, Hu Y, Xie T. Clinicopathological and prognostic significance of cyclooxygenase-2 expres- sion in head and neck cancer: A meta-analysis. Oncotarget. 2016;7:47265-47277.
55. Ogawa M, Koitabashi A, Takayama Y, et al. Clinicopathological ex- amination of expression of COX-2 and PGES in oral squamous cell carcinama. Oral Science in Japan. 2015;2015:11-14.